

## Immunology and Hematology: A Comprehensive Clinical Update On Demand

Premier Sponsor



Immunology and Hematology: A Comprehensive Clinical Update Agenda		
Module	Topic	Presenter(s)
Module 1	<p>Immune Thrombocytopenia</p> <ul style="list-style-type: none"> <li>Describe recent advances in the understanding of ITP pathogenesis</li> <li>Develop a diagnostic plan for a thrombocytopenic patient to confirm an ITP diagnosis</li> <li>Develop an appropriate therapeutic plan for ITP patients, individualizing therapy based on disease severity</li> </ul>	<i>Dr. Dana LeVine</i>
Module 2	<p>Immune-Mediated Hemolytic Anemia</p> <ul style="list-style-type: none"> <li>Explain how immunodiagnostic testing can be optimized for diagnosis of IMHA in dogs</li> <li>Evaluate the pros and cons of different immunosuppressive regimens for treatment of IMHA</li> <li>Design a rational plan for antithrombotic treatment in dogs with IMHA according to clinical need</li> </ul>	<i>Dr. James Swann</i>
Module 3	<p>Feline Immune-Mediated Diseases</p> <ul style="list-style-type: none"> <li>Describe the clinical features of major immune-mediated diseases of cats</li> <li>Explain how immunodiagnostic testing should be adapted for diagnosis of immune-mediated diseases in cats</li> <li>Assess pharmacokinetic and pharmacodynamic factors that influence effective delivery of immunosuppressive drugs in cats</li> </ul>	<i>Dr. James Swann</i>
Module 4	<p>Immunosuppression: Overview and Management of Immune-Mediated Diseases</p> <ul style="list-style-type: none"> <li>Better understand immunosuppressive therapies and how they can be successfully used for the treatment of immune-mediated disorders</li> <li>Recognize how to assess the response of patients to immunosuppressive therapy, and when and how to make dose adjustments</li> </ul>	<i>Dr. John Thomason</i>
Module 5	<p>Advanced Therapies for Immune-Mediated Diseases: TPE</p> <ul style="list-style-type: none"> <li>Understand the mechanisms of plasma exchange, the necessary equipment, and the challenges to patient safety during treatment</li> <li>Recognize which diseases may benefit from therapeutic plasma exchange, which patients would benefit from referral, and understand the common treatment schedules</li> </ul>	<i>Dr. JD Foster</i>

## Immunology and Hematology: A Comprehensive Clinical Update On Demand

*Premier Sponsor*



Module 6	<p>Group Panel Discussion/Q&amp;A: Optimizing Patient Management for Immune-Mediated Hematologic Diseases</p> <ul style="list-style-type: none"> <li>Recognize the benefits and drawbacks of tests available for diagnosing immune-mediated hemolytic anemia in dogs and cats</li> <li>Recognize gaps in our knowledge regarding optimal immunomodulatory therapy for canine and feline immune-mediated diseases</li> <li>Understand the application of advanced therapies, such as total plasma exchange, for treatment of immune-mediated disease</li> </ul>	<i>Dr. Shauna Blois,          Dr. JD Foster,          Dr. Dana LeVine,          Dr. James Swann,          Dr. John Thomason</i>
Module 7	<p>Bone Marrow Disorders: Part I</p> <ul style="list-style-type: none"> <li>Recognize the normal structure of trabecular bone marrow, including non-hematopoietic elements in bone marrow that support hematopoiesis</li> <li>Outline the maturational stages of hematopoiesis</li> <li>Describe the dynamics of white blood cell, red blood cell and platelet responses to peripheral demands</li> <li>Recognize the cellular targets of hematopoietic growth factors in clinical use and the physiological response</li> </ul>	<i>Dr. Dorothee Bienzle</i>
Module 8	<p>Bone Marrow Disorders: Part II</p> <ul style="list-style-type: none"> <li>List the diagnostic features and causes of hematopoietic insufficiency, including toxic, infectious and nutritional etiologies</li> <li>Explain differences in clinical presentation and diagnostic features of myeloid and lymphoid leukemia</li> <li>Define the key diagnostic features of acute leukemia, myelodysplastic syndrome and myeloproliferative neoplasms</li> <li>Recognize the indications and utility of ancillary tests such as flow cytometry, immunohistochemistry and PARR to investigate bone marrow diseases</li> </ul>	<i>Dr. Dorothee Bienzle</i>
Module 9	<p>The CBC Cytogram in Immune-Mediated Hemolytic Anemia and Immune-Mediated Thrombocytopenia – <b>Presented by IDEXX</b></p> <ul style="list-style-type: none"> <li>Understand technology of advanced hematology analyzers</li> <li>Understand cytograms in the diagnosis and management of IMHA and ITP</li> <li>Understand cytogram appearance in other cytopenia cases</li> </ul>	<i>Dr. Heidi Peta,          Dr. Kim Yore</i>
Module 10	<p>Infectious Hematologic Disorders: Part I – Understanding and Diagnosing Infectious Causes of Immune-Mediated Diseases</p> <ul style="list-style-type: none"> <li>Integrate pathophysiologic principles of how infection may cause immune-mediated disease into the way you think about diagnosing and treating immune-mediated hematologic disease</li> <li>Recognize common infectious causes of immune-mediated hematologic disease</li> <li>Optimize diagnostic testing for vector-borne disease in patients with immune-mediated hematologic disease</li> </ul>	<i>Dr. Linda Kidd</i>

## Immunology and Hematology: A Comprehensive Clinical Update On Demand

*Premier Sponsor*



Module 11	<p>Infectious Hematologic Disorders: Part II – Case Management in Immune-Mediated Diseases with Possible Infectious Diseases</p> <ul style="list-style-type: none"> <li>• Determine when to use immunosuppressive therapies in dogs and cats when the underlying disease process has not been established as either infectious or immune-mediated</li> <li>• Determine how to react to a patient that has received immunosuppressive and developed a secondary infection</li> </ul>	<i>Dr. John Thomason</i>
Module 12	<p>Transfusion Medicine</p> <ul style="list-style-type: none"> <li>• Determine when crossmatching is appropriate</li> <li>• Recognize the varying situations in which plasma product transfusions may, or may not, be helpful</li> <li>• Evaluate whether storage lesions should affect clinical practice decisions</li> </ul>	<i>Dr. Karen Humm</i>
Module 13	<p>Group Panel Discussion/Q&amp;A: Challenges in the Diagnosis and Management of Hematologic Diseases</p> <ul style="list-style-type: none"> <li>• Recognize the benefits and limitations of bone marrow testing in the diagnostic approach to hematologic disease</li> <li>• Identify features of the CBC cytogram that aid in the diagnosis of immune-mediated hematologic disease</li> <li>• Recognize how to manage patients with immune-mediated disease when infections have not been ruled out</li> <li>• Describe best practices for safe and effective blood transfusions in patients with immune-mediated hematologic disease</li> </ul>	<i>Dr. Dorothee Bienzle,            Dr. Shauna Blois,            Dr. Karen Humm,            Dr. Linda Kidd,            Dr. John Thomason</i>
Module 14	<p>Overview of Hemostasis</p> <ul style="list-style-type: none"> <li>• Relate the cascade model of coagulation to interpretation of clotting time tests and coagulation factor assays</li> <li>• Understand how the cell-based model of coagulation integrates the role of platelets and coagulation complex assembly in promoting clot formation and explains the action of new oral anticoagulant drugs</li> <li>• Apply the clot lifespan model to evaluate fibrinolytic pathways and interpret viscoelastic test</li> </ul>	<i>Dr. Marjory Brooks</i>
Module 15	<p>Case Studies in Hypercoagulability</p> <ul style="list-style-type: none"> <li>• Identify patient risk factors for hypercoagulability and thromboembolic complications</li> <li>• Select and interpret diagnostic results for patients with suspected hypercoagulability or thromboembolic disease</li> <li>• Develop appropriate treatment and monitoring plans for patients with hypercoagulability and thromboembolic disease</li> </ul>	<i>Dr. Shauna Blois</i>

**Immunology and Hematology: A Comprehensive Clinical Update  
On Demand**

*Premier Sponsor*



Module 16	<p>Case Studies in Hypocoagulability</p> <ul style="list-style-type: none"> <li>• Develop a diagnostic and treatment plan for hemorrhagic defects</li> <li>• Select and interpret appropriate ancillary diagnostic tests for definitive diagnosis of hemostatic disorders</li> <li>• Become familiar with new therapies for patients with complex primary, secondary, and tertiary hemostatic defects</li> </ul>	<i>Dr. Marjory Brooks, Dr. Dana LeVine</i>
Module 17	<p>Group Panel Discussion/Q&amp;A: Hemostasis</p> <ul style="list-style-type: none"> <li>• Recognize challenges in the diagnosis of hemostatic disorders</li> <li>• Understand how to approach the diagnosis and treatment of hypercoagulability and thrombosis</li> <li>• Understand how to approach the diagnosis and treatment of hypocoagulability</li> </ul>	<i>Dr. Shauna Blois, Dr. Marjory Brooks, Dr. Karen Humm, Dr. Dana LeVine</i>